Clinical trial of dry eye treatment drug reproxalap clinical 2b yields positive results

dry eye disease is a common inflammatory disease that affects about 20 million people in the United StatesThe disease is characterized by inadequate moisture and lubrication on the front surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, reduced quality of life and, in severe cases, permanent vision impairmentrecently, Aldeyra(indicating that the company'sdrug(Clinical 2b Clinicaltrial) for dry eye treatment has(positive results)ReproxalapReproxalap is a candidate for theof aldeyra's mainproduct (a RASP inhibitor that achieves eye disease treatment by reducing the level of aldehyde molecules in pro-inflammatory." The drug, which is a local eye drop, is the first treatment for dry eye disease and other eye inflammation (first-in-class) therapy, and is currently in the late stages of clinical developmentthis randomized, placebo-controlled, parallel-group, multicenter, double-blind 2b clinical trial, the efficacy of 0.1% and 0.25% of reproxalap local eye solutioncompared to placebo was studiedCompared to patients with placebo, patients with a 0.25% concentration drug therapy group with a four-symptom eye dryness score (p0.05) and overall eye discomfort symptom score (Overall Ocular Discomfort Score) (p05) there was a significant and clinical decrease (p0.05)In all scoring tests, reproxalap improved symptoms more significantly than the symptoms in the control group, and showed an improvement in the disease as early as two weeks (the first assessment after the start of treatment)The early effect of symptom improvement is consistent with the clinical Phase 2a trial of the drug and is different from the current standard of care In addition, the eye fluorocoin dying score in patients with 0.25% concentration was also significantly lower than that of the control group, with a statistically significant difference (P 0.05) The 0.1% and 0.25% of the concentrationof of reproxalap showed activity relative to the control group and a significant dose response was observed Consistent with previous clinical trials, reproxalap is well tolerated and reported adverse reactions are generally minor in addition, aldeyra has initiated a clinical trial to observe the dermatological manifestations of the treatment of Sj?g?gren-Larsson syndrome (SLS) in the form of local drugs to improve the symptoms of this severe skin disease, known as "fish scale disease," as reproxalap has been shown in preclinical studies to form the chelation of fatty aldehydes in human skin cells The disease is thought to be caused by the accumulation of aldehydes inherent in SLS and is currently to the FDA (no targeted therapies approved)